PELL Bio-Med Technology Co (TPE:6949) Stock Based Compensation: NT$68.42 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6949 PELL Bio-Med Technology Co Ltd TPE:6949
13 GF Score
Price NT$991.00
! 5 Warning Signs
View Full Analysis

What is PELL Bio-Med Technology Co Stock Based Compensation?

PELL Bio-Med Technology Co TPE:6949 -3.79% 13 Stock Based Compensation is NT$68.42 Mil as of Mar. 2026. GuruFocus rates TPE:6949 with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

PELL Bio-Med Technology Co's Stock Based Compensation for the three months ended in Mar. 2026 was NT$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was NT$68.42 Mil.

PELL Bio-Med Technology Co Stock Based Compensation Related Terms

PELL Bio-Med Technology Co Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for PELL Bio-Med Technology Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PELL Bio-Med Technology Co Stock Based Compensation Chart

PELL Bio-Med Technology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
24.96 46.68 143.06 58.97 75.12

PELL Bio-Med Technology Co Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.70 0.39 0.00 68.03 0.00
TPE:6949
13GF Score
PELL Bio-Med Technology Co Ltd TPE:6949
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PELL Bio-Med Technology Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$68.42 Mil.

What does a Stock Based Compensation of NT$68.42 Mil mean?
PELL Bio-Med Technology Co (TPE:6949) has a Stock Based Compensation of NT$68.42 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for PELL Bio-Med Technology Co and its competitors.
Is PELL Bio-Med Technology Co's Stock Based Compensation too high?
PELL Bio-Med Technology Co's current Stock Based Compensation is NT$68.42 Mil. Overall, PELL Bio-Med Technology Co has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does PELL Bio-Med Technology Co's Stock Based Compensation compare to VRTX and REGN?
PELL Bio-Med Technology Co's Stock Based Compensation of NT$68.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for PELL Bio-Med Technology Co and its competitors. PELL Bio-Med Technology Co's current Stock Based Compensation is NT$68.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PELL Bio-Med Technology Co stock overvalued right now?
PELL Bio-Med Technology Co (TPE:6949) has a current Stock Based Compensation of NT$68.42 Mil. The current Stock Based Compensation is NT$68.42 Mil. PELL Bio-Med Technology Co's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For PELL Bio-Med Technology Co (TPE:6949), the current Stock Based Compensation is NT$68.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PELL Bio-Med Technology Co Business Description

Address No. 87, Xinhu 2nd Road, 4th Floor, Neihu District, Taipei, TWN
PELL Bio-Med Technology Co Ltd is a company engaged in the research and development and application of autologous T Cell Therapy (Adoptive T Cell Therapy), CAR-T (Chimeric Antigen Receptor T cell), and Gene-Modified Adipose-Derived Stem Cell (Gene-Modified Adipose-Derived Stem Cell). The company's segments includes Cell products, Consulting services, and Others.
13GF Score

Get the complete analysis for TPE:6949

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$991.00
Price